Shandong Weigao Group Medical Polymer Company Limited (WEIGAO GROUP) disclosed a next-day return confirming the on-market repurchase of 100,000 H shares on 6 July 2026. The shares were bought at prices between HKD 3.21 and HKD 3.22, with a volume-weighted average cost of HKD 3.218 per share, for a total consideration of HKD 0.32 million.

Following the transaction: • Issued share capital (excluding treasury shares) decreased marginally to 4,462.03 million shares, down 0.0022% from 4,462.13 million. • Treasury share holdings rose to 60.30 million shares. • Total issued shares, including treasury stock, remained unchanged at 4,522.33 million.

The buyback forms part of the mandate approved by shareholders on 29 May 2026, which authorises the company to repurchase up to 446.46 million shares. Cumulative repurchases under this mandate have reached 2.98 million shares, representing 0.67% of the shares outstanding at the mandate date. In line with Hong Kong Stock Exchange rules, WEIGAO GROUP is subject to a moratorium on issuing, selling or transferring shares until 5 August 2026.